Daiichi Sankyo, AstraZeneca sign $6.9 billion cancer drug deal
AstraZeneca Plc and Japan’s Daiichi Sankyo Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Daiichi’s cancer drug trastuzumab deruxtecan.
[stock-ticker]
